Clinical Research Directory

Inclusion Criteria: * Histologically-proven localized prostate cancer. * Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor) * Low-risk: cT1-T2a, PSA \<10, and Gleason score 6 * Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7 * High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7 * Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume * Planned for EBRT (+/- ADT) * ECOG 0 or 1 * 18 years of age or older * Ability to provide written informed consent to participate in the study Exclusion Criteria: * Prior radiotherapy to pelvis * Radiological evidence of regional or distant metastases at the discretion of the treating physician. * Active ulcerative colitis or Crohn's Disease, at discretion of treating physician * Ataxia Telangectasia and SLE * Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury * Severe claustrophobia